DTI (Direct thrombin inhibitor) peptides and application thereof

Abstract

The invention belongs to the field of biotechnology, and relates to a direct thrombin inhibitor polypeptide and its application. On the basis of the structure of RGD-Hirudin, the present invention truncates its molecules to obtain the direct thrombin inhibitor small molecule polypeptides Peptide 1 and Peptide 2; after testing and animal experiments, the results show that the polypeptides Peptide 1 and Peptide 2 are The direct thrombin inhibitor has antithrombin activity, its drug target is clear, and has no effect on other blood coagulation factors, and can be further prepared for oral or subcutaneous slow-release anticoagulant drugs, and is especially suitable for preventing thrombotic diseases; the present invention The polypeptide can also be used as a candidate drug for direct thrombin inhibitors for in-depth research, laying the foundation for the development of new direct thrombin inhibitors.

Description

technical field [0001] The invention belongs to the field of biological technology, and relates to an anticoagulant polypeptide and its application, especially a direct thrombin inhibitor polypeptide and its application. Background technique [0002] The prior art discloses that the research and development of direct thrombin inhibitors (DTIs) play an important role in the prevention and treatment of cardiovascular and cerebrovascular diseases such as venous and arterial thrombosis, heparin-induced thrombocytopenia (HIT) and acute coronary ischemic syndrome. played a huge role. Said DTIs have distinct advantages over traditional anticoagulants (heparin and vitamin K (VKAs)); injectable DTIs and oral DTIs are known to be used clinically. However, practice shows that the indications of the above-mentioned injection DTIs and oral DTI drugs are still single, and each DTI is only for a specific disease, and the treatment cost is expensive; therefore, the development of new injec...

AI Technical Summary

Problems solved by technology

However, practice shows that the indications of the above-mentioned injection DTIs and oral DTI drugs are still single, and each DTI is only for a specific disease, and the treatment cost is expensive; therefore, the development of new injection and oral DTIs is important in the treatment and Promising potential for preventing thromboembolic disease

[0003] The inventors of the present application have previously developed a novel bifunctional fusion protein RGD-hirudin, which has dual functions of antithrombin and antiplatelet aggregation. RGD-Hirudin is a protein / polypeptide drug. As a direct thrombin inhibitor, it can only be administered through intravenous injection, which obviously limits its clinical application

Images